Company Overview and News
Amicus Therapeutics (FOLD) saw a 19% rise in its stock in the week ended May 18. On May 18, Amicus Therapeutics stock closed at $16.74, a 126% increase from its 52-week low of $7.41 on May 18, 2017. Amicus Therapeutics stock has risen 116% over the past year.
Amicus Therapeutics (FOLD) is dedicated to the development and marketing of drugs for rare and orphan conditions:
Editor's note: Seeking Alpha is proud to welcome The Sensible Steward as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
Eli Lilly & Co. will buy the immuno-oncology biotech ARMO Biosciences Inc. for about $1.6 billion in an all-cash deal, the company announced early Thursday. ARMO Biosciences shares surged 77.6% in premarket trade after the news, while Eli Lilly shares were inactive. ARMO's lead product candidate, pegilodecakin, is in a late-stage clinical trial for pancreatic cancer and in earlier trials for lung and renal cell cancer, melanoma and other solid tumors.
Table of Contents
CRANBURY, N.J., May 09, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Tuesday, May 15, 2018 at 9:20 a.m. P.T.
Good day, ladies and gentlemen, and welcome to the Amicus Therapeutics First Quarter 2018 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today's conference is being recorded.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
QuickLinks -- Click here to rapidly navigate through this document
CRANBURY, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2018.
NEW YORK, NY--(Marketwired - April 25, 2018) - ELUCIDA ONCOLOGY, INC®, a biotechnology company focused on developing and commercializing a first-in-class, ultra-small nanoparticle platform technology for the diagnosis and treatment of cancer, announced today that it has appointed Robert A. Essner as its Executive Chairman. Mr. Essner was Chairman and Chief Executive Officer for Wyeth, acquired by Pfizer in 2009.
Today's fund in the spotlight, Baker Brothers, has been struggling of late but as long term investors they´ve chalked up an impressive track record.
Investors in Amicus Therapeutics, Inc. (FOLD - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 4, 2018 $16.00 Call had some of the highest implied volatility of all equity options today.
Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET